Cynata Therapeutics Limited (CYYNF)
USD 0.19
(0.0%)
USD 0.19
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.96 Million | -14.28 Million | -3.29 Million | -5.16 Million | -3.38 Million | -6.75 Million |
| Net Income | -9.74 Million | -14.27 Million | -5.44 Million | -7.68 Million | -3.63 Million | -8.47 Million |
| Depreciation & Amortization | 280.73 Thousand | 279.96 Thousand | 279.96 Thousand | 279.96 Thousand | 280.73 Thousand | 279.96 Thousand |
| Deferred income taxes | - | -326.54 Thousand | -1.03 Million | -1.53 Million | -388.23 Thousand | -904.3 Thousand |
| Stock-based compensation | - | 326.54 Thousand | 1.03 Million | 1.53 Million | 388.23 Thousand | 904.3 Thousand |
| Change in working capital | -726.42 Thousand | -684.05 Thousand | 1 Million | 755.33 Thousand | -615.16 Thousand | 594.82 Thousand |
| Other non-cash items | 1.54 Million | 398.85 Thousand | 860.37 Thousand | 1.49 Million | 585.85 Thousand | 838.27 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 6.72 Million | 210.12 Thousand | 18.19 Million | 10.05 Million | 1.53 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -317.82 Thousand | - | -571.95 Thousand | -406.92 Thousand | -75.51 Thousand |
| Common Stock Issuance | - | 6.72 Million | - | 18.3 Million | 9.38 Million | 1.4 Million |
| Other Financing Activities | - | 317.82 Thousand | 210.12 Thousand | 462.27 Thousand | 1.08 Million | 200 Thousand |
| Accounts receivables | 362.8 Thousand | -356.39 Thousand | 20.3 Thousand | -156.68 Thousand | 152.06 Thousand | 40.66 Thousand |
| Accounts payables | -1.11 Million | -259.97 Thousand | 951.68 Thousand | 740.93 Thousand | -780.91 Thousand | 533.61 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 27.53 Thousand | -67.68 Thousand | 34.51 Thousand | 171.08 Thousand | 13.68 Thousand | 20.54 Thousand |
| Cash at beginning of period | 16.16 Million | 23.79 Million | 26.71 Million | 13.64 Million | 6.97 Million | 12.2 Million |
| Cash at end of period | 6.2 Million | 16.16 Million | 23.79 Million | 26.71 Million | 13.64 Million | 6.97 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | -72.3 Thousand | 169.58 Thousand | 33 Thousand | -15.00 | 12.00 |
| Net cash flow / Change in cash | -9.96 Million | -7.63 Million | -2.91 Million | 13.06 Million | 6.67 Million | -5.22 Million |
| Free Cash Flow | -9.96 Million | -14.28 Million | -3.29 Million | -5.16 Million | -3.38 Million | -6.75 Million |
| Breakdown | 2024 FY | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.74 Million | -2.27 Million | -2.27 Million | -14.27 Million | -9.1 Million | -4.55 Million |
| Depreciation & Amortization | 280.73 Thousand | - | - | 279.96 Thousand | 139.98 Thousand | 69.99 Thousand |
| Deferred income taxes | - | - | - | -326.54 Thousand | -102.29 Thousand | - |
| Stock-based compensation | - | 39.03 Thousand | 39.03 Thousand | 326.54 Thousand | 34.37 Thousand | 34.37 Thousand |
| Change in working capital | -726.42 Thousand | - | - | -684.05 Thousand | -212.03 Thousand | -212.03 Thousand |
| Other non-cash items | 1.54 Million | -194.84 Thousand | -194.84 Thousand | 398.85 Thousand | 2.23 Million | 1.15 Million |
| Investing Cash Flow | - | - | - | - | 19.42 Thousand | -16.28 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | 6.72 Million | 6.72 Million | 3.36 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -317.82 Thousand | - | - |
| Common Stock Issuance | - | - | - | 6.72 Million | 6.72 Million | - |
| Other Financing Activities | - | - | - | 317.82 Thousand | 3.36 Million | 3.36 Million |
| Accounts receivables | 362.8 Thousand | - | - | -356.39 Thousand | -178.19 Thousand | -178.19 Thousand |
| Accounts payables | -1.11 Million | - | - | -259.97 Thousand | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 27.53 Thousand | - | - | -67.68 Thousand | -33.84 Thousand | -33.84 Thousand |
| Cash at beginning of period | 16.16 Million | - | - | 23.79 Million | 16.41 Million | 16.41 Million |
| Cash at end of period | 6.2 Million | -2.5 Million | -2.5 Million | 16.16 Million | 16.16 Million | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | -73.73 Thousand | -73.73 Thousand | -72.3 Thousand | 19.42 Thousand | 19.42 Thousand |
| Net cash flow / Change in cash | -9.96 Million | -2.5 Million | -2.5 Million | -7.63 Million | -244.29 Thousand | -16.41 Million |
| Free Cash Flow | -9.96 Million | -2.42 Million | -2.42 Million | -14.28 Million | -7 Million | -3.5 Million |
UAMY
SASOF
1711
ESTER
BZ
9723